Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Black cohosh warning unnecessary – ABC

This article was originally published in The Tan Sheet

Executive Summary

A cautionary statement for black cohosh is not warranted, the American Botanical Council says in an Oct. 31 letter to the U.S. Pharmacopeia. USP recommended in an Interim Revision Announcement appearing in USP's Pharmacopeial Forum that black cohosh products should carry the statement: "Caution: In rare cases black cohosh has been reported to affect the liver. Discontinue use and consult a health care practitioner if you have a liver disorder or develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice." According to ABC, "reported cases of hepatotoxicity associated with the ingestion of black cohosh preparations constitute insufficient evidence to warrant the proposed caution by USP or any reputable regulatory body at this time." The group says given the implementation of FDA's Adverse Event Reporting regulation for dietary supplement firms, "it would seem more prudent to suggest a framework for enhanced attention to black cohosh reported incidents received through this new system"...

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts